Metagenomics analysis reveals universal signatures of the intestinal microbiota in colorectal cancer, regardless of regional differences

L. Berbert2*, A. Santos1*, D.O. Magro2*, D. Guadagnini1*, H.B. Assalin1*, L.H. Lourenço2*, C.A.R. Martinez2*, M.J.A. Saad1*, and C.S.R. Coy2*

1Departamento de Medicina Interna, Universidade Estadual de Campinas, Campinas, SP, Brasil
2Departamento de Cirurgia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brasil

Abstract

The human gut microbiota is a complex and dynamic community of microorganisms living in our intestines and has emerged as an important factor for colorectal adenocarcinoma (CRC). The purpose of our study was to investigate the microbiota composition in Brazilian CRC patients compared with a local control population (CTL) to find out which changes could be considered universal or regional features in CRC microbiota. Fecal samples were obtained from 28 CRC and 23 CTL individuals. The 16S rRNA gene was used for metagenomic analysis. In addition to the anthropometric variables, the clinical stage (TNM 2018) was considered. Patients with CRC had a significant increase in alpha diversity and a higher percentage of genus Prevotella and a decreased proportion of Megamonas and Ruminococcus. Additionally, the proportion of Faecalibacterium prausnitzii was associated with a better prognosis in the first stages of CRC, and Fusobacterium nucleatum proved to be an important marker of colorectal carcinogenesis and tumor aggressiveness. Although regional differences influence the composition of the microbiota, in the case of CRC, the microhabitat created by the tumor seems to be a major factor. Our results contribute to a better understanding of the carcinogenic process, and even in different environments, some factors appear to be characteristic of the microbiota of patients with CRC.

Key words: Gut microbiota; Colorectal cancer; Faecalibacterium prausnitzii; Fusobacterium nucleatum; Dysbiosis

Introduction

Colorectal cancer (CRC) is one of the most common neoplasms worldwide. The prevalence of CRC is about 4.8 million people, and the number of new cases increases each year. There are many factors involved in somatic cell transformation through the wrong path of mutations in colorectal carcinogenesis (1). The heredity component in colon cancer is between 12 and 35% (2), reflecting the environmental importance in its development. This process occurs due to the sum of genetic predisposition, disruption in immune system response, environmental damage such as through food, and microbiota alterations (3).

The human gut microbiota is a complex and dynamic community of microorganisms living in our intestines and has emerged as an important factor for CRC (4). In addition to colon cancer, disorders in the microbiota composition are associated with many diseases. Therefore, inflammatory bowel disease, type 2 diabetes mellitus, and CRC all have a common ground: they are proven to be linked with intestinal dysbiosis that results in homeostasis changes and affects local and systemic immunity, creating a chronic inflammatory environment (4). In this environment, host defenses, cell cycle, apoptosis, and anti-oxidative defenses are modulated and reactive oxygen species and nitrous oxide system production leads to DNA damage (5).

Previous data show that the geographic location of the host has the strongest association with microbiota modulation, indicating the relevance of the environment in this modulation and suggesting that CRC microbiota signature can be different in different countries and cultures (6). Recent studies indicate that although the same disease is being studied, differences in the microbiota may produce different changes that may result in a better or worse patient response (7). The Brazilian population has particularities due to its great ethnic and cultural variety and there are few studies that evaluated the
microbiota in Brazilian CRC patients (8–10). In this regard, the purpose of our study was to investigate microbiota composition of Brazilian CRC patients compared with a local control population, in order to determine which changes can be considered universal or regional features of the CRC microbiota. In addition, our data can contribute to establish a possible microbiota signature that can be used as a predictor for CRC diagnosis, prognosis, and future treatment.

Material and Methods

Ethical statement

Subjects who agreed to participate in the study signed an informed consent form. This research was performed according to the relevant guidelines and regulations. The study was approved by the local Institutional Ethics Review Board in Brazil (CEP - Comitê de Ética em Pesquisa at Unicamp), under reference number 8.857.49/14 for the data collected from control subjects and protocol number 2.144.670/17 for the data collected from cancer patients.

Study design and population

This was an observational cross-sectional single center study (Colorectal Unit of Campinas State University, Unicamp, Brazil) with CRC patients and control subjects (CRC, colorectal adenocarcinoma patients and CTL, subjects who underwent CRC screening with normal colonoscopy or adenomas). The following exclusion criteria were applied: current use of antibiotics or chemotherapy, adenomas with high grade dysplasia, subjects without criteria for colorectal screening colonoscopy, previous colectomy procedures, intestinal stomas, radiotherapy, inflammatory bowel disease, chronic liver disease, and familial adenomatous polyposis.

Clinical data, location, and stage of CRC (TNM 2018), history of breastfeeding and type of delivery, and morbidity were analyzed. The anatomic classification of the tumor’s location was proximal colon (cecum, ascending colon, transverse colon), distal colon (descending colon, sigmoid, rectum), or synchronous. One day before colonoscopy, all participants received a liquid diet and ingested 500 mL of 10% mannitol diluted in 1000 mL of water. On the day of colonoscopy, the same nurse in the clinic collected the first stool, avoiding contamination and loss of material. All feces were solid. The feces were collected in a sterile toilet seat liner (ColOff™, Brazil). About 200 mg of the sample was transferred to a tube (STRATEC Biomedical AG, Germany) that preserves DNA/RNA and immediately frozen at –80°C for one week until DNA extraction.

Metagenome profile

Total DNA of fecal samples was extracted using the Stool PSP Spin DNA kit (STRATEC Biomedical AG), an integrated system for collecting, transporting, and storing fecal samples and subsequent DNA purification. For microbiota profiling, the hyper-variable region (V3-V4) of the bacterial 16S rRNA gene was amplified following the Illumina 16S Metagenomic Sequencing Library Preparation guide (USA), which uses the following sequence: 338F-5’TGCCTCCGCAACGCTATGTGATAAGAGACAG CCTACGGNGGCWGCAG-3 and 785R-5’ GTCTCGTGGG GCCTCGAGATGTGTGATAAGACAGACGGACTACHVGGGTATCTAAATCCT-3’ (2 × 300 bp paired-end and insert size of ~550 bp).

Bioinformatics analysis

To determine the taxonomic composition of bacterial communities, we analyzed the V3 and V4 portion of 16S gene rRNA using the Illumina® MiSeq platform. The DNA sequencing library was built according to platform instructions. Using paired reads of 300 bp and MiSeq v3 reactors, the end of each reading was overlapped to generate high-quality full readings of the V3 and V4 region. More than 100,000 readings per sample were generated, which is sufficient for metagenomics research. The fastq sequences were analyzed using Illumina 16S Metagenomics software (analysis software version: 2.4.60.8; reference taxonomy file: gg_13_5_species_32 bp.da), which performs taxonomic classification of the V3 / V4 region of the 16S rRNA gene using the GreenGenes database. The analysis of gut microbiota genera was performed by the Galaxy software (open-source) and LDA-LEfSe (The Huttenhower Lab, USA), an algorithm for the identification of large biomarkers, which characterizes differences between biological conditions. The LEfSe program provides a list of the different taxa between the control group and the patient group according to effect size. The abundant taxa from the control group (green) or the patients (red) are given a positive or negative linear discriminant analysis (LDA) score, respectively (LDA rate >2 and significance <0.05, determined by the Wilcoxon test). LDA by effect size (LEfSe) was used to identify taxa that discriminated microbiota profiles of control and patient groups. Alpha diversity analysis was performed using the phyloseq package2 (MicrobiomeAnalyst: R version 3.6.3 (2020-02-29); web-based tool). The results were plotted across samples and reviewed as box plots for each group (11).

Statistical analysis

The sample size was calculated based on the relative contribution of proteobacteria percentage. Assuming for α and β errors of 5% (power 95%), 26 subjects were needed in each group. The calculations were performed using G* Power software version 3.1.2 (program concept and design written by Franz University Kiel, Germany, which is freely available for Windows).

Fischer exact and the chi-squared tests were used for qualitative variables and a frequency table was built for categorical variables. Data from cancer patients and...
control groups are reported as means ± SD or medians and interquartile range (IQR, 25–75%) for continuous variables. The Mann-Whitney U-test (non-parametric distribution) was used for comparison of continuous variables between categories. To correlate intestinal bacterial species with clinical stage disease, the Spearman test was used.

The significance level was 5% (P-value < 0.05) and the SPSS v. 25.9 software (IBM Inc., USA) was used for statistical analysis.

Results

Study population characteristics
Between 2017 and 2018, a total of 51 subjects were included, 28 in CRC and 23 in CTL.

The baseline characteristics of the groups are detailed in Table 1. There were no significant differences between the groups regarding age (65.18 ± 12.27, 52.04 ± 10.08, P=0.292), body mass index (26.39 ± 5.06, 27.14 ± 5.52 kg/m², P=0.526), and gender (P=0.75).

Distal colon (57.1%) was the most frequent CRC location. Regarding TNM classification, early stages were the most common, accounting for 42.9% of the sample (stages 0 and I), stage II 25%, stage III 28.6%, and stage IV 3.6%.

Intestinal microbiota analysis
Regarding alpha diversity (Figure 1), analyzed with Simpson and Shannon models, CTL had greater diversity (P < 0.01). Both models consider the number of present species and the relative abundance of each species (Simpson’s values vary between 0 and 1 and Shannon’s between 1.5 and 3.0). There was no significant difference in the proportion of the main bacterial phyla (Figure 2).

LEfSe (Figure 3) results indicated genus differences between groups (rate with an LDA score >2 and a significance of <0.05, Wilcoxon signed rank-test) with Prevotella predominance in CRC and Meganonas and Ruminococcus predominance in CTL.

There were no differences between groups regarding the species Akkermansia muciniphila, Faecalibacterium prausnitzii, Lachnospira pectinoschiza, Peptostreptococcus anaerobius, Escherichia coli, and Enterococcus faecalis.

Higher amounts of Prevotella copri (P=0.029), Bacteroides fragilis (P=0.032), and Fusobacterium nucleatum (P=0.03) were observed in CTL and a greater abundance of Bacteroides vulgatus (P=0.002), Bacteroides stercoris (P=0.01), Bacteroides uniformis (P=0.02), and Phascolarctobacterium faecium (P=0.01) occurred in CRC (Figure 4).

There was an inverse correlation between cancer stage and Prevotella copri (Spearman R=−0.5666, P=0.003), Lachnospira pectinoschiza (Spearman R=−0.4222 P=0.041), Faecalibacterium prausnitzii (Spearman R=−0.488 P=0.016), and Streptococcus bovis (Spearman R=−0.482 P=0.012), i.e., the higher the clinical stage, the lower the amount of these species (Figure 5).

Discussion

Our study found that Brazilians with CRC have an altered gut microbiota composition, characterized by increased alpha diversity and different amounts of some genera and species.

Similar to our results, other Brazilian studies have also found an increase in alpha diversity in CRC biopsy samples (8,10). In the same way, B. fragilis, a symbiotic organism common in the human intestinal tract, was found to be more abundant in tumor samples (12) and CRC stool samples (8). This species can adhere to the inflamed mucosal surface of patients with colon cancer, alter intestinal permeability, and increase metastatic potential (13). There are two subtypes, one of which is enteropathogenic (14). The toxin released by this subtype (Bacteroides fragilis toxin) increases cell proliferation, the release of pro-inflammatory factors by the colonic epithelium, and damage to DNA (15).

Although the population studied by de Carvalho et al. (10), Thomas et al. (8), and our study was from the Brazilian state of São Paulo, the abundance of some genera was not similar in the three studies. Thomas et al. (8) and de Carvalho et al. (10) showed that the genus Odoribacter was increased in the CRC group (8,10), which was not found in our samples. The genus Ruminococcus was found depleted in the CRC group by de Carvalho et al. and our study but not by Thomas et al. Similarly, de Carvalho et al. (10) and Thomas et al. (8) diverged in the abundance of other genera. These differences may be due to the 16S RNA region of choice on the bacterial community for sequencing the 16S gene (16).

Similar results regarding alpha diversity were shown among groups in a large meta-analysis from 5 countries that included 413 subjects with CRC, 143 adenomas, and 413 controls (17). In contrast, some studies have described a decrease in alpha diversity associated with CRC in stool samples (18). In an Austrian study, the alpha diversity showed no difference between healthy control subjects with advanced adenomas and CRC patients (19).

Individuals with CRC have a higher percentage of genera Prevotella and Acidaminobacter and a relatively decreased proportion of Meganonas and Ruminococcus. Prevotella has already been associated with increased production of IL-17 in the mucosal cells of patients with CRC (20,21). Acidaminobacter was also found to be over-represented in CRC stool samples (22). Ruminococcus genera are related to the fermentation of complex carbohydrates and producers of short-chain fatty acids. This genus and Meganonas were increased in the control group in our study, which is in line with other studies (19).

In a cohort study with healthy controls and CRC patients from the United States and Canada, there was an
increase in *Fusobacterium* and *Porphyromonas* and a decrease in *Bacteroides* (23). The CRC group had increased *Prevotella copri*, *Bacteroides fragilis*, and *Fusobacterium nucleatum* species. In the control group, there was a predominance of *Bacteroides vulgatus*, *Bacteroides stercoris*, and *Bacteroides faecium* species.

The increase of *Prevotella copri*, *Lachnospira pectinoschiza*, *Faecalibacterium prausnitzii*, and *Streptococcus bovis* was associated with early cancer stages. *Streptococcus bovis* (*Streptococcus gallolyticus*) was the first species described in the literature to be related to CRC. McCoy and Mason (24) reported endocarditis due to

---

**Table 1.** Baseline characteristics of control (CTL) and colorectal adenocarcinoma (CRC) groups.

| Variables                        | CRC | CTL | P-value |
|----------------------------------|-----|-----|---------|
| **n=28**                         |     |     |         |
| Gender (%)                       |     |     |         |
| Male                             | 50.0| 65.2| 0.75    |
| Female                           | 50.0| 34.8|         |
| Age (mean ± SD)                  | 65.18±12.27| 52.04±10.08| 0.29    |
| BMI (kg/m²) (mean ± SD)          | 26.39±5.06| 27.14±5.52| 0.52    |
| Home location (%)                |     |     |         |
| Rural                            | 3.6 | 0   | 1.00    |
| Urban                            | 96.4| 100 |         |
| Delivery (%)                     |     |     |         |
| Vaginal                          | 100 | 87  | 0.08    |
| C-section                        | 0   | 13  |         |
| Last antibiotic treatment (%)    |     |     |         |
| Weeks                            | 7.1 | 4.3 |         |
| 1–3 months                       | 14.3| 0   |         |
| 3–6 months                       | 3.6 | 0   | 0.38    |
| 6–12 months                      | 7.1 | 4.3 |         |
| More than 12 months              | 64.3| 91.3|         |
| Unknown                          | 3.6 | 0   |         |
| Smoking Status (%)               |     |     |         |
| Current smoker                   | 10.7| 13  | 0.62    |
| Never smoker                     | 82.1| 69.6|         |
| Ex-smoker                        | 7.1 | 17.4|         |
| Breastfeeding (%)                |     |     |         |
| Until 6 months                   | 10.7| 8.7 |         |
| 6–12 months                      | 21.4| 26.1|         |
| More than 12 months              | 28.6| 34.8| 0.75    |
| Unknown                          | 28.6| 17.4|         |
| Never                            | 7.1 | 13  |         |
| Morbidity (%)                    |     |     |         |
| Diabetes                         | 17.9| 0   | 0.07    |
| Hypertension                     | 35.7| 13.0| 0.18    |
| Thyroid disease                  | 7.1 | 0   | 0.28    |
| Dyslipidemia                     | 7.1 | 4.3 | 1.00    |
| Lupus                            | 7.1 | 0   | 0.28    |
| Diverticular disease             | 25.0| 26.1| 0.53    |
| Tumor location (n. %)            |     |     |         |
| Proximal colon (cecum, ascending colon, transverse colon) | 10 (35.7) | – | – |
| Distal colon (descending colon, sigmoid, rectum) | 16 (57.1) | – | – |
| Synchronous                      | 2 (7.2) | – | – |
| TNM classification (%)           |     |     |         |
| Stages 0 and I                   | 42.9| –   |         |
| Stage II                         | 25.0| –   |         |
| Stage III                        | 28.6| –   |         |
| Stage IV                         | 3.6 | –   |         |

Data were compared by Fischer exact test, chi-squared test, or Mann-Whitney U-test. TNM: tumor, node, metastasis.
this species in a patient with a colon tumor in 1951. The current study showed a correlation of *S. bovis* with early disease stages. This finding may be related to the CRC individuals having a higher proportion of initial tumors and all cases being located in the proximal colon. Therefore, it should not be assumed that the presence of *S. bovis* is associated with less tumor aggressiveness, but only with its proximal location. Results similar to those reported in the literature are also expected for tissue samples, as a higher prevalence was observed when the microbiota was analyzed from biopsies rather than fecal samples (25). The hypothesis is that such a species can adhere to the tissue and induce a pro-inflammatory environment that can lead to tumor progression, especially in pre-neoplastic lesions (26).

In our study, larger amounts of *Prevotella copri* and *F. prausnitzii* were also observed in the early stages of disease. *Prevotella copri* has a controversial role in human health (27). Some articles relate this species to vegetarian and fiber-rich diets, suggesting that *P. copri* helps in fiber degradation and related to health condition (14,28). It is associated with the production of short-chain fatty acids, which are believed to play a crucial role in the development of colorectal cancer (4).
which is the substrate that nourishes enterocytes and has anti-inflammatory effects (29). In contrast, other authors have shown that the increase in the amount of *P. copri* is related to inflammatory conditions, such as rheumatoid arthritis (30) and insulin resistance (31). These controversial results can be justified by the variation in genotypes.

---

**Figure 4.** Comparison of the relative abundance of bacterial species in the intestinal microbiota of the control (CTL) and colorectal adenocarcinoma (CRC) groups.

**Figure 5.** Spearman’s correlation between cancer staging and bacterial composition. Inverse correlation between cancer staging and A. *Prevotella copri* (Spearman R = -0.5866 P = 0.003); B. *Lachnospira pectinoschiza* (Spearman R = -0.4222 P = 0.041); C. *Faecalibacterium prausnitzii* (Spearman R = -0.488 P = 0.016); and D. *Streptococcus bovis* (Spearman R = -0.482 P = 0.012).
of this species, which is mainly modulated by diet, as demonstrated by De Filippis et al. (21). Furthermore, bacteria of this genus have been associated with CRC (32).

In contrast, *Fusobacterium prausnitzii* is a butyrate-producing bacteria, being considered the most important of the human intestinal microbiota, commonly associated with health status (29,33). Clinical staging is currently the most important indicator of prognosis in patients with CRC. However, new strategies to identify prognostic predictors are being investigated. The species *F. prausnitzii* was found in greater quantity among patients who had longer postoperative survival (34) and can be a marker of lower aggressiveness.

Finally, *Fusobacterium nucleatum* was shown to be an important marker of colorectal carcinogenesis and tumor aggressiveness (35). It is known that *F. nucleatum* can adhere to the epithelium, and when it invades, it recruits immune cells and creates an inflammatory environment by modulating the response of T cells and promoting metastasis (36,37). A Brazilian study found more *F. nucleatum* and *Clostridium difficile* in the CRC fecal samples (9). de Carvalho et al. showed higher quantities of *F. nucleatum* in tumor tissue, which was associated with more undifferentiated invasive proximal tumors, loss of expression of MLH1 and MSH2 PMS2, and worse prognosis (10). In a study in Sweden using combined tests for *Escherichia coli* and *F. nucleatum*, CRC was detected with a specificity of 63.1% and a sensitivity of 84.6% (38). Similarly, our findings were compatible with current data and confirmed that *F. nucleatum* can be considered an important marker of colorectal carcinogenesis and tumor aggressiveness, since alterations in tumor environment may favor proliferation of opportunistic bacteria (39). As seen previously, this species is found in greater numbers in patients with CRC around the world and in Brazil. Zeller et al. (40), using a similar method, evaluated French subjects and found that *F. nucleatum* was one of the four most important species correlated with cancer diagnosis.

Our study had limitations. First, the sample size was small, and the cross-sectional design did not allow determination of cause-effect relationships. In addition, to understand the functional features of the species, all its genetic compounds must be analyzed, which is possible using the shotgun method rather than by 16S RNA. Another characteristic of this sample that may have affected the results was that almost 43% were early-stage tumors.

Conclusions

We have demonstrated that gut dysbiosis is associated with CRC. Patients with CRC had a significant increase in alpha diversity and a higher percentage of the genus *Prevotella* and a decreased proportion of *Megasphaera* and *Ruminococcus*. Additionally, the proportion of *F. prausnitzii* was associated with a better prognosis in the first stages of CRC, and *Fusobacterium nucleatum* proved to be an important marker of colorectal carcinogenesis and tumor aggressiveness. Although regional differences influence the composition of the microbiota, the microhabitat created by CRC seems to be a major factor. Our results contribute to a better understanding of the carcinogenic process, and, even in different environments, some factors appear to be characteristic of the microbiota of patients with CRC.

Acknowledgments

The authors would like to acknowledge the financial support of INCT (National Institute of Science and Technology for Diabetes and Obesity: 465693/2014-8-CNpq) and FAPESP (2014/50907-5).

References

1. Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. *Mol Nutr Food Res* 2017; 61; doi: 10.1002/mnr.21500902.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000; 343: 78–85; doi: 10.1056/NEJM200007133430201.
3. Wroblewski LE, Peek RM, Coburn LA. The role of the microbiome in gastrointestinal cancer. *Gastroenterol Clin North Am* 2016; 45: 543–556; doi: 10.1016/j.gtc.2016.04.010.
4. Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. *Annu Rev Microbiol* 2016; 70: 395–411; doi: 10.1146/annurev-micro-102215-095513.
5. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 2012; 338: 120–123; doi: 10.1126/science.1224820.
6. He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. *Nat Med* 2018; 24: 1532–1535; doi: 10.1038/s41591-018-0164-x.
7. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. *Nature* 2016; 555: 210–215; doi: 10.1038/nature25973.
8. Thomas AM, Jesus EC, Lopes A, Aguiar S Jr, Begnami MD, Rocha RM, et al. Tissue-associated bacterial alterations in rectal carcinoma patients revealed by 16S rRNA community profiling. *Front Cell Infect Microbiol* 2016; 6: 179; doi: 10.3389/fcimb.2016.00179.
9. Fukugaiti MH, Ignacio A, Fernandes MR, Ribeiro Júnior U, Nakano V, Avila-Campos MJ. High occurrence of *Fusobacterium nucleatum* and *Clostridium difficile* in the intestinal microbiota of colorectal carcinoma patients. *Braz J Microbiol* 2015; 46: 1135–1140; doi: 10.1590/S1517-8382201400665.
10. de Carvalho AC, de Mattos Pereira L, Datore JG, Dos Santos W, Berardinelli GN, Matsushita MM, et al. Microbiota profile and impact of *Fusobacterium nucleatum* in colorectal cancer patients at Barretos Cancer Hospital. *Front Oncol* 2019; 9: 813, doi: 10.3389/fonc.2019.00813.

11. Darwai A, Chong J, Habib S, King IL, Agellon LB, Xia J. Microbiome Analyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. *Nucleic Acids Res* 2017; 45: W180–W188, doi: 10.1093/nar/gkx295.

12. Wang T, Cai G, Qiu Y, Zhang M, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J* 2012; 6: 320–329, doi: 10.1038/ismej.2011.109.

13. Sears CL, Geis AL, Houssseau F. *Bacteroides fragilis* subverts mucosal biology: from symbiont to colon carcinogenesis. *J Clin Invest* 2014; 124: 4166–4172, doi: 10.1172/JCI72334.

14. De Filippis F, Pellegrini N, Laghi L, Gobbetti M, Ercolini D. Unusual sub-genus associations of faecal *Prevotella* and *Bacteroides* with specific dietary patterns. *Microbiome* 2016; 4: 57, doi: 10.1186/s40168-016-0202-1.

15. Viljoen KS, Daekshinamurthy A, Goldberg P, Blackburn JM. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between *Fusobacterium spp.*, *enterotoxigenic Bacteroides fragilis* (ETBF) and clinicopathological features of colorectal cancer. *PLoS One* 2015; 10: e0119462, doi: 10.1371/journal.pone.0119462.

16. Bukin YS, Galachyants YP, Morozov IV, Bukin SV, Zakharenko AS, Zemskaya TI. The effect of 16S rRNA region choice on bacterial community metabarcoding results. *Sci Data* 2019; 6: 190007, doi: 10.1038/sdata.2019.7.

17. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanes A, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nat Med* 2019; 25: 679–689, doi: 10.1038/s41591-019-0406-6.

18. Ahn J, Sinha R, Pei Z, Dominiani C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. *J Nat Cancer Institute* 2013; 105: 1907–1911, doi: 10.1093/jnci/djt300.

19. Feng Q, Liang S, Jia H, Stadlmayr A, Tan L, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. *Nat Commun* 2015; 6: 6528, doi: 10.1038/ncomms7528.

20. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriallt ML, Van Nhieu JT, et al. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? *Ther Adv Gastroenterol* 2013; 6: 215–229, doi: 10.1177/1756283X12473674.

21. De Filippis F, Pascoli E, Tett A, Tarallo S, Naccaratti A, De Angelis M, et al. Distinct genetic and functional traits of human intestinal *Prevotella copri* strains are associated with different habitual diets. *Cell Host Microbe* 2019; 25: 444–453.e3, doi: 10.1016/j.chom.2019.01.004.

22. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. *PLoS One* 2013; 8: e70803, doi: 10.1371/journal.pone.0070803.

23. Zackular JP, Rogers MA, Ruffin 4th MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. *Cancer Prev Res (Phila)* 2014; 7: 1112–1121, doi: 10.1158/1940-6207.

24. McCoy WC, Mason 3rd JM. Enterococcal endocarditis associated with carcinoma of the sigmoid; report of a case. *J Med Assoc State Ala* 1951; 21: 162–166.

25. Bolej A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus galactylcoccus infection among colorectal cancer patients: systematic review and meta-analysis. *Clin Infect Dis* 2011; 53: 870–878, doi: 10.1093/cid/cir609.

26. Rezasoltani S, Aghdahi HA, Dabiri H, Sepahi AA, Modarresi MH, Mojadar EN. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. *Microb Pathog* 2018; 124: 244–249, doi: 10.1016/j.micpath.2018.08.035.

27. Ley RE. Gut microbiota in 2015: Prevotella in the gut: choose carefully. *Nat Rev Gastroenterol Hepatol* 2016; 13: 69–70, doi: 10.1038/nrgastro.2016.4.

28. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut* 2016; 65: 1812–1821, doi: 10.1136/gutjnl-2015-309957.

29. O’Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. *Nat Rev Gastroenterol Hepatol* 2016; 13: 691–706, doi: 10.1038/nrgastro.2016.165.

30. Scher JU, Szczesniak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *Elife* 2013; 2: e01202, doi: 10.7554/eLife.01202.

31. Pedersen HK, Gudmundsdottir V, Nielsen HB, Høybylained T, Nielsen T, Jensen BA, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* 2016; 535: 376–381, doi: 10.1038/nature18646.

32. Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E. Microbiome in colorectal cancer: how to get from metat-omics to mechanism? *Trends Microbiol* 2020; 28: 401–423, doi: 10.1016/j.tim.2020.01.001.

33. Bressa C, Bailén-Andrino M, Pérez-Santiago J, González-Soltero R, Pérez M, Montalvo-Lominchar MG, et al. Differences in gut microbiota profile between women with active lifestyle and sedentary women. *PLoS One* 2017; 12: e0171352, doi: 10.1371/journal.pone.0171352.

34. Wei Z, Cao S, Liu S, Yao Z, Sun T, Li Y, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. *Oncotarget* 2016; 7: 46158–46172, doi: 10.18632/oncotarget.10064.

35. Amitay EL, Werner S, Vital M, Pieper DH, Höfler D, Gierse IJ, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. *Carcinogenesis* 2017; 38: 781–788, doi: 10.1093/carcin/bgx053.

36. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. *Carcinogenesis* 2017; 38: 781–788, doi: 10.1093/carcin/bgx053.

37. Mima K, Sukawa Y, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. *Fusobacterium nucleatum* in colorectal carcinoma
38. Eklöf V, Löfgren-Burström A, Zingmark C, Edin S, Larsson P, Karling P, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer 2017; 141: 2528–2536, doi: 10.1002/ijc.31011.

39. Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol 2020; 11: 615056, doi: 10.3389/fimmu.2020.615056.

40. Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 2014; 10: 766, doi: 10.15252/msb.20145645.